EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The story of elimination of visceral leishmaniasis (kala-azar) in India—Challenges towards sustainment

Shyam Sundar iD

PLOS Neglected Tropical Diseases · 2025

DOI: 10.1371/journal.pntd.0013321 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PLOS Neglected Tropical Diseases, 2025. Verfasst von Shyam Sundar. Beteiligte Einrichtung: Department of General Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. Hauptthemen laut MEDLINE: Leishmaniasis, Visceral, Disease Eradication. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The earliest record of visceral leishmaniasis (kala-azar, KA, VL) dates back two centuries from Jessore (now in Bangladesh), with 0.75 million deaths in 3 years. In the 1950s, there was extensive insecticide dichlorodiphenyltrichloroethane (DDT) spray under the aegis of the National Malaria Eradication Program. As a corollary benefit, there was a sharp decline in the incidence of VL due to the reduced prevalence of the vector to extremely low levels, resulting in substantial decreases in the number of KA cases. In the early 1970s, a surge in the number of cases was noted, and since then, it has taken the shape of the current epidemic. In 1990–91, the National Kala-azar Control Program was launched in India, though without much impact due to the diminishing efficacy of treatment with pentavalent antimonial. This was followed by the introduction of highly effective amphotericin B deoxycholate. In 2005, the Kala-azar Elimination Program (KAEP) was launched jointly by India, Bangladesh, and Nepal, with treatment initially with oral miltefosine, succeeded later by single-dose liposomal amphotericin B (AmBisome), and in 2023, India achieved the goal of kala-azar elimination, defined as an incidence below 1 per 10,000 at sub-district (block) level. Patients with post kala-azar dermal leishmaniasis, HIV-VL coinfection, and undiagnosed/untreated VL patients are the human sources for the vector. They may herald an outbreak resulting in the commencement of a new epidemic. Active case detection, early diagnosis, and prompt, complete treatment are required to prevent fresh transmission. Periodic updates of health personnel, community awareness, and continued availability of the theragnostics are important steps for early detection and containment of an outbreak.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leishmaniasis, VisceralDisease EradicationIndiaHumansAntiprotozoal AgentsPhosphorylcholineAnimalsBangladeshIncidenceAmphotericin B

Substanzen

Antiprotozoal AgentsPhosphorylcholineAmphotericin B

Autor:innen und Institutionen

  • Department of General Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.

ORCID-Profile: Shyam Sundar

Zitieren

APA

Sundar, S. (2025). The story of elimination of visceral leishmaniasis (kala-azar) in India—Challenges towards sustainment. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0013321

Vancouver

Sundar S. The story of elimination of visceral leishmaniasis (kala-azar) in India—Challenges towards sustainment. PLOS Neglected Tropical Diseases. 2025. doi:10.1371/journal.pntd.0013321

BibTeX
@article{Sundar2025,
  author = {Sundar, Shyam},
  title = {The story of elimination of visceral leishmaniasis (kala-azar) in India—Challenges towards sustainment},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2025},
  doi = {10.1371/journal.pntd.0013321}
}
Kostenlos starten →